Healthcare & Pharmaceuticals

France says it has ordered 50,000 doses of Merck's COVID-19 antiviral pill

1 minute read

The Merck logo is seen on a sign at the Merck & Co campus in Rahway, New Jersey, U.S., July 12, 2018. REUTERS/Brendan McDermid

PARIS, Oct 26 (Reuters) - France has ordered 50,000 doses of Merck & Co's (MRK.N) experimental COVID-19 antiviral drug for adults, the country's health minister Olivier Veran told a hearing at the French Senate on Tuesday.

"France positioned itself very early in pre-ordering. France ordered 50,000 doses of the drug," Veran told lawmakers about molnupiravir, which is Merck & Co's experimental antiviral pills to treat COVID-19 ailments.

Governments around the world are preparing to ensure they can cope any pick-up in the COVID virus as the winter season approaches in the northern hemisphere.

Merck & Co said on Monday that the European Union's drug regulator had initiated a real-time review of its experimental COVID antiviral drug for adults. read more

While vaccines are the main weapons against COVID-19, Merck's experimental pill molnupiravir could be a game-changer after studies showed it could halve the chances of dying or being hospitalised for those most at risk of contracting severe illness.

Register now for FREE unlimited access to Reuters.com
Reporting by Matthieu Protard; Editing by Sudip Kar-Gupta

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters